Solt DB is a public benefit company exploring the business of biotech. The finch helps investors learn about science and scientists learn about business.
Subscriptions to investment research ensure our platform has long-term sustainability. That strong foundation allows us to create value for the public benefit.
The finch publishes free, objective analyses of the bioeconomy. We combine clear writing and data visualizations to make nerdy technical concepts accessible, so you can go beyond the headlines on a noisy internet. Subscriptions also allow us to self-fund the development of high quality, open source data assets such as the Solt DB Biotech Company Database. Our unique business model means our incentives are never tied to advertising, clickbait, or corporate sponsors.
Solt DB was founded by a bioprocess engineer who became a financial analyst. Writing thousands of articles for mass media publications provided a front-row seat to how the internet works -- and it's not always pretty.
The dependence on advertising revenue or corporate sponsors can quickly warp incentives, such as prioritizing clickbait and headlines engineered to tickle algorithms over competence. This model predictably leads to errors, inaccuracies, and a poor understanding of some of the most important technologies of the 21st century.
Solt DB was founded as a public benefit company to align our incentives with people, not algorithms. The finch generates 100% of revenue from subscriptions, so we're never tempted to write clickbait or take money from corporate sponsors.
Our platform is truly independent.
Solt DB uses the same illustration tools as scientists publishing in the world's top journals -- a first in finance.
The combination of simple language and clear visuals allows investors of all backgrounds to more deeply understand the biotech stocks they own, while scientists can gain a better grasp of the business of biotech.
We don't tell you about biotech. We show you.
Solt DB leverages interactive data visualizations to discuss and analyze living technology in vivid detail. From individual company insights to broad trends across competitive landscapes, the finch helps you objectively understand the bioeconomy -- even when trends don't match the headlines.
Click or hover these charts to view data labels.
We don't tell you every stock is a buy. Sometimes good businesses and promising technologies platforms are overvalued -- and it's okay to admit that.
Solt DB Invest quantifies its written research with a real-time Margin of Safety, which shows how much stocks need to rise or fall to reach our fair value.
This chart is interactive, too.